Page 3 - HFA_Dateline_2017_Q2_Fall_Special_Edition

Assisting and advocating for the bleeding In This Issue:
disorders community since 1994.
4 Executive Corner
Special Issue Fall 2017 6 Product Evolution:

EXECUTIVE LEADERSHIP Decades of Innovation

Board Chair 9 Current Products on the Market
Tracy Cleghorn
19 Emerging Therapies
President & CEO
Kimberly Haugstad, MBA 24 Learn About Clinical Studies

PRODUCTION TEAM Informed 27 Informed Consent:
Consent:
Editor A Process, A Process, Not Just a Form
Kyle McKendall Not Just
a Form
Copy Editor
Kit Salisbury By HFA Staff

Design & Layout 30 O h, The Places We’ll Go! Novel Therapies for Hemophilia and
Kristin Mitchell Design, Inc.
Other Bleeding Disorders
CONTRIBUTORS
32 US Food and Drug Administration’s Drug Approval Process
Shannon Carpenter, MD, MS 36 A ccess Challenges for New Treatments
US National Library of Medicine
Katie Verb, JD, Staff
Sonji Wilkes, Staff

The information printed in
Dateline Federation is provided for
general purpose use. HFA does not give
medical advice or engage in the practice of
medicine and recommends that you consult
with your physician or local treatment center
before beginning any form of treatment.

Requests for permission to translate or
reprint contents of Dateline Federation should
be directed to info@hemophiliafed.org.

820 First Street NE, Suite 720
Washington, DC 20002
800.230.9797
info@hemophiliafed.org

©2017 Hemophilia Federation of America.
All rights reserved.

To subscribe to receive Dateline Federation
in the mail for free, visit www.hemophiliafed.org
or send your name and address to
info@hemophiliafed.org.

Special Issue Fall 2017 | Dateline Federation 3